Compare FormFactor Inc. FormFactor Inc. Common Stock (FORM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FormFactor Inc. FormFactor Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $117.41 (market cap $10.01B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.7× FormFactor Inc. FormFactor Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, FormFactor Inc. FormFactor Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| FORM | NTRA | |
|---|---|---|
Market Cap | $10.01B | $57.03B |
Volume | 1,445,909 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $159.93 | $425.64 |
52-Week Low | $41.29 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.69B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FormFactor (FORM) trades at $128.09, down 1.68% on the day, amid a bullish technical setup with key support at $127. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28. Revenue and net income are projected to grow significantly in 2026, though valuation ratios remain elevated.
The outlook is positive, driven by strong AI-driven semiconductor demand and strategic collaborations, but high P/E and P/S ratios pose valuation risks. Analyst consensus is bullish with a $154.71 price target, though insider selling and negative cash flow in 2025 warrant caution.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FormFactor Inc. FormFactor Inc. Common Stock
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
